Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 10Lung Neoplasms 9Colorectal Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Rectal Neoplasms 7Adenocarcinoma of Lung 7Colonic Neoplasms 5Adenocarcinoma, Bronchiolo-Alveolar 4Glioblastoma 3Brain Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Inflammatory Breast Neoplasms 2Gliosarcoma 2Carcinoma 2Breast Neoplasms, Male 2Unspecified Adult Solid Tumor, Protocol Specific 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Non Small Cell Lung Cancer Metastatic 1Meningioma 1Medulloblastoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Glioma 1Fallopian Tube Neoplasms 1Erythema Multiforme 1Ependymoma 1Cognition Disorders 1

Interventions

Mental Status and Dementia Tests 1Lomustine 1DNA Methylation 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Cognition Disorders × Bevacizumab × Clear all
NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
592 enrolled
CNS

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡